820 results about "Ovary" patented technology

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The invention provides a method for preparing a chicken immortalized cell line. The method comprises the following steps: constructing a plasmid system of conditional over-expression TERT (Telomerase Reverse Transcriptase), carrying out ovarian injection and breeding to obtain a transgenic chicken of the conditional over-expression TERT, and carrying out separation and induction to obtain the chicken immortalized cell line. The obtained chicken immortalized cell line has the characteristics of primary cells and is susceptible to viruses; the method can be used for virus reproduction and detection, influenza virus vaccine production and the like, can obtain immortalized cell lines of all organs and all parts of the chicken in a short time, and has a good application prospect in the vaccine industry.

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The present disclosure provides a Chinese Hamster Ovary (CHO) cell comprising one or more exogenous nucleotide sequences, wherein the one or more exogenous nucleotide sequences is inserted into a chromosomal locus of the CHO cell, wherein the chromosomal locus is located within contig NW_023276805.1 of chromosome X. Also provided herein are methods of producing a CHO cell capable of expressing a sequence of interest, methods of expressing a sequence of interest comprising culturing the CHO cell as described herein, and kits comprising the CHO cell as described herein.

The invention provides an establishment method of umbilical cord mesenchymal stem cells with high expression of IGF-1 (Insulin-like Growth Factor 1) and application of the umbilical cord mesenchymal stem cells in premature ovarian failure. The construction method of the umbilical cord mesenchymal stem cells with high expression of IGF-1 comprises the step of transfecting the umbilical cord mesenchymal stem cells with the IGF-1 gene, so that the umbilical cord mesenchymal stem cells highly express IGF-1. The invention also provides application of the umbilical cord mesenchymal stem cell with high expression of IGF-1 in preparation of drugs for treating premature ovarian failure. According to the invention, the IGF-1 gene is transfected to the hUC-MSC, so that the hUC-MSC highly expresses the IGF-1, and the hUC-MSC secretes a large amount of IGF-1. The ovarian function is improved through the immunoregulation effect of hUC-MS, and meanwhile, the effect of resisting apoptosis of granular cells is achieved through IGF-1 secreted by hUC-MS. And the treatment effect on the premature ovarian failure is achieved through synergism of the two effects.

The embodiment of the invention discloses an ovarian health assessment method and related equipment, the method is applied to first electronic equipment, the first electronic equipment can display a first interface, and the first interface comprises a first control; receiving a first operation acting on the first control; acquiring first data, wherein the first data comprises heart rate variability data of the user in a preset time period; according to the physical sign data of the user, determining an ovary health assessment result; the user sign data comprises first data; the ovarian health assessment result is used for indicating the ovarian health condition of the user in a preset time period; after the preset time period, a second interface is displayed, and the display content of the second interface comprises the ovarian health assessment result. By adopting the method, the ovarian function abnormity of the user can be found in time.

The invention discloses application of a substance for detecting the expression level of APOE or MT2 in evaluating the ovarian aging degree. According to the invention, cell and molecular changes related to ovarian aging are explored in spatial resolution by adopting a spatial transcriptome technology, a first non-human primate space-time transcriptome map is established, and potential diagnostic biomarkers and therapeutic targets of age-related human ovarian diseases are disclosed; the method not only promotes the understanding of primate ovarian aging mechanism determinants, but also provides abundant resources for identifying cells and molecular programs which can be used for evaluating ovarian aging and formulating intervention measures for human ovarian aging and related diseases.

The invention provides a preparation method of ovarian stem cells and application of the ovarian stem cells in ovarian aging resistance. More specifically, ovarian stem cells and polypeptide LRP-C5 which is separated from pilose antler polypeptide and has a good ovarian aging treatment effect are prepared and screened from ovaries, ovarian aging of rats can be well treated after the ovarian stem cells and the polypeptide LRP-C5 are used independently or jointly, and the application prospect is good.

The invention discloses application of MY-1B in preparation of medicines for improving ovarian aging, belongs to the technical field of biological medicines, and aims to solve the problems of how to effectively delay ovarian aging and improve ovarian functions. Experiments prove that the mRNA m5C modification level of ovarian granular cells in the ovarian aging process is increased, and the expression level of methylated transferase Nsun2 is increased. Ovarian aging caused by mRNA m5C modification level increase can be improved by supplementing the MY-1B, which is embodied in that the MY-1B can reduce the mRNA m5C modification level of aging nest granular cells; the MY-1B can be used for effectively correcting the orbital cycle disorder of the aged ovary and delaying the decline of the ovarian function; the MY-1B plays an important role in reducing the apoptosis level of granulosa cells in senescent ovaries; the MY-1B can improve the storage capacity of ovaries and enhance the quality of oocytes, so that the fertilization rate and the embryonic development potential of the oocytes are improved.

The invention discloses an artificial intelligence-driven polycystic ovarian syndrome drug target screening method, which comprises the following steps: S1, collecting genome data and hormone level data from the body of a patient, and constructing a patient individualized data set; s2, carrying out denoising processing, missing value filling and standardization on the acquired individual data set of the patient; s3, inputting the standardized individual data set of the patient into a multi-layer neural network model; s4, training the dynamic gene-hormone interaction network model by adopting the training set data; s5, screening out dual regulation and control drug targets highly related to the PCOS pathological mechanism; s6, performing optimization through historical treatment data of the patient and target treatment effect feedback; and S7, outputting the dual regulation and control drug target list in a report form. According to the invention, the efficiency and accuracy of drug target screening are significantly improved.

The invention provides application of sturgeon swimming bladder collagen peptide in preparation of a medicine for premature ovarian failure, and relates to the technical field of protein peptide. According to the method, the sturgeon swim bladder is subjected to resource utilization, so that the waste of the sturgeon swim bladder can be effectively reduced, the sturgeon resource can be sustainably utilized, the extraction rate of the sturgeon swim bladder collagen is relatively high, and industrial production is facilitated; meanwhile, collagen peptide obtained after enzymolysis treatment is conducted through alkaline protease can achieve the effects of preventing, treating, inhibiting and improving the premature ovarian failure.

The invention relates to the technical field of biomedical treatment, in particular to bifidobacterium longum subsp. Longum and application thereof in drugs related to reproductive system diseases. The invention provides a strain of Bifidobacterium longum subsp. Longum NCU-06, which is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation date is January 18, 2023, and the preservation number is CGMCC No.26491. The invention also provides a method for preparing the Bifidobacterium longum subsp. Longum NCU-06. The bifidobacterium longum subsp. Longum NCU-06 has a treatment effect on various female reproductive system diseases, for example, the bifidobacterium longum subsp. Longum NCU-06 can be used for treating endometriosis, ovarian cancer, ovarian cancer parneoplastic thrombocythemia and ovarian hyperstimulation syndrome.

The invention belongs to the technical field of medicines, and particularly relates to a composition containing mesenchymal stem cells and application of the composition in preparation of products for resisting premature ovarian failure. The invention relates to a composition containing mesenchymal stem cells. The umbilical cord mesenchymal stem cell gel is prepared from the following components in percentage by weight: 10 percent of umbilical cord mesenchymal stem cells, 4 to 6 percent of human serum albumin stock solution, 1 to 2 percent of ginkgo biloba extract, 1 to 3 percent of coix seed oil, 2 to 2.5 percent of flavonol glycoside, 1.1 to 1.3 percent of vitamin E, 0.4 to 0.8 percent of glutathione, 0.5 to 1.5 percent of sodium hyaluronate, 0.5 to 1.0 percent of phycocyanin, 1.2 to 1.8 percent of zinc gluconate, 0.5 to 0.8 percent of heparin calcium, 0.1 to 0.3 percent of pH regulator and the balance of normal saline. The composition disclosed by the invention can be used for preparing products for resisting premature ovarian failure and has a very good effect.

The invention discloses an ovary-targeting mRNA liposome nanoparticle, a preparation method, a drug compound, a targeting delivery system and application, and relates to the technical field of liposome granules, the ovary-targeting mRNA liposome nanoparticle comprises the following components by mass: 20%-80% of SM-102, 1%-20% of PEG2000, 5%-40% of CHO-HP, 1%-20% of DSCP, and 0.01%-10% of targeting polypeptide, the target polypeptide comprises at least one of the following sequences: LVYKDPARPNTQK, RCGPCRLSSSDCGGPRTQPMACDLP, and CALCRRSTSDCGGPKDHPLT (recombinant human serum albumin), and the target polypeptide comprises at least one of the following sequences. The present invention provides a liposome nanoparticle for targeted ovary and uterus delivery of mRNA. The lipidosome nano-particles are specially researched, developed and designed for mRNA, have a good targeted delivery effect in mRNA in-vivo delivery, and can be applied to the field of targeted drug delivery of ovaries and uteruses. When in use, the kit can be directly prepared with a specific mRNA sequence for use, so that different application requirements can be flexibly met.

The invention discloses a probe and a primer for detecting the expression quantity of sex determining gene amhr2 of silurus meridionalis, the probe comprises an amhr2T probe and an amhr2G probe, and the primer comprises an upstream primer F1 and a downstream primer R1, the invention also discloses a kit comprising the probe and the primer, a method for detecting the expression quantity of the sex determining gene amhr2 of the catfish by using the probe and the primer, application of the probe and the primer in preparation of the kit for detecting the expression quantity of the sex determining gene amhr2 of the catfish, and the probe and the primer. The kit or the method is applied to the detection of the expression quantity of the sex determining gene amhr2 of the silurus meridionalis. The probe and the primer provided by the invention can accurately detect the expression quantity of the ovary or testis amhr2 gene in silurus asotus, and are low in cost, high in efficiency and high in accuracy.

The invention provides a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following medicines in parts by mass: 9-30 parts of radix astragali preparata, 6-20 parts of roasted rhizoma atractylodis macrocephalae, 10-15 parts of poria cocos, 2-10 parts of radix glycyrrhizae preparata, 6-20 parts of semen cuscutae, 9-20 parts of radix dipsaci (dipsacus root), 6-12 parts of herba lycopi and 6-15 parts of lily. Experimental results show that the traditional Chinese medicine composition is suitable for improving the ovarian function of a patient suffering from spleen-kidney deficiency type ovarian reserve function decline.

Compositions including FSH and hCG for use in the treatment of infertility.

The invention belongs to the technical field of biology, and particularly relates to a receptor peptidomimetic capable of improving the breeding efficiency of butter crabs and application of the receptor peptidomimetic. The optimal binding conformation is screened according to the sequence prediction binding conformation of the vitellogen and the receptor of the vitellogen, the hotspot residues are screened according to the optimal binding conformation, and the binding energy change before and after mutation of the hotspot residues is calculated to determine the receptor peptidomimetic sequence. The receptor peptidomimetic can obviously slow down the development speed of the ovary of the blue crab and effectively induce the formation of the butter crab by utilizing the specificity of specific recognition of the vitellogenin of the blue crab and the receptor, so that the butter crab product can be produced in a planned manner.

The invention relates to the technical field of ovarian granule cell apoptosis, and discloses a method for regulating oxidative stress induced sheep ovarian granule cell apoptosis by using allicin, and the method comprises the following steps: firstly preparing a culture solution, then preparing an allicin stock solution, and identifying sheep ovarian granule cells; the method comprises the following steps: firstly, measuring the activity of ovarian granular cells after independent treatment of H2O2 and allicin, determining the optimal treatment time and concentration of H2O2 and allicin, then carrying out co-treatment of H2O2 and allicin, detecting the apoptosis of the granular cells by using flow cytometry, detecting the expression of apoptosis-related genes by using real-time fluorescent quantitative PCR, detecting the secretion of steroid hormones by using ELISA, and carrying out data analysis. The invention solves the problems that in the prior art, an effective regulation and control method for ovarian granular cell apoptosis induced by oxidative stress is lacked, and traditional medicines possibly have large side effects, unobvious effects and the like.

The invention discloses a steady-state magnetic field generating device for ovarian function adjustment, and belongs to the technical field of biological medicine, the steady-state magnetic field generating device comprises a magnetic field generator and a base for supporting and fixing the magnetic field generator, and a placing table for placing a mouse cage is arranged in the middle in the base; the magnetic field generator comprises four layers of main magnets and edge compensation magnets which are arranged according to an annular array arrangement mode, and horizontal magnet rings are arranged above the uppermost main magnet and below the lowermost main magnet; the main magnet, the edge compensation magnet and the horizontal magnet ring are fixed on the mounting frame through epoxy resin; the steady-state magnetic field generating device treats a POI mouse through the magnetic field intensity of 100-400 mT, and the result shows that the steady-state magnetic field generating device has important potential in the aspect of repairing ovarian injury or improving the ovarian function of the POI mouse and has good clinical application prospects.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

The present invention belongs to the technical field of plant extracts, and more specifically, relates to the use of a carob extract in a drug for improving glucose metabolism / polycystic ovary syndrome in women. The present invention discloses a pharmaceutical composition for improving glucose metabolism and treating polycystic ovary syndrome in women, the pharmaceutical composition comprising: carob extract, baicalein, cedrol, a bioactive peptide, a biopolysaccharide, and excipients. The composition of the present invention has the effects of lowering blood sugar and blood lipids, improving insulin function, and also has antioxidant and immunity-enhancing effects. By combining the above substances, a synergistic effect is achieved, further enhancing the effect of improving / treating polycystic ovary syndrome in women associated with abnormal glucose metabolism.

The invention belongs to the technical field of biology, and particularly relates to a CHO cell suspension culture medium as well as a preparation method and application thereof. The culture medium comprises amino acids, vitamins, inorganic salts, trace elements, carbohydrates and other molecular compounds; the amino acids comprise glycine, L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and L-valine. The culture medium provided by the invention can meet the high-density suspension culture of various CHO cells, can improve the production efficiency and reduce the production cost, and has wide application prospects and values. The culture medium provided by the invention overcomes the defects of the existing culture medium with determined chemical components, and provides more choices for the culture medium with determined chemical components in China.

The invention discloses a health-care food for delaying ovarian aging, which belongs to the technical field of health-care foods and comprises a composition for improving the levels of anti-mullerian test tube hormone and superoxide dismutase and functional auxiliary materials, the composition for improving the anti-muller test tube hormone and superoxide dismutase level is prepared from the following components in parts by weight: 2 to 5 parts of pyrroloquinoline quinone PQQ, 30 to 80 parts of cranberry powder and 40 to 100 parts of an isoflavone extract, and the content of the pyrroloquinoline quinone PQQ is 2 to 5 parts, the content of the cranberry powder is 30 to 80 parts, and the content of the isoflavone extract is 40 to 100 parts. The pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract in a specific formula have the effect of synergistically improving the levels of anti-muller test tube hormone and superoxide dismutase, and the health food prepared from the pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract can improve sleep, improve urinary tract infection of middle-aged women, delay ovarian aging and the like.

The invention discloses a method for efficient maturation of ovaries of industrially cultured plectropomus leopardus. The method comprises the following steps: screening healthy plectropomus leopardus individuals from a plectropomus leopardus population as parent fishes; putting the fish in an indoor culture pond for water adaptation to obtain high-quality parent fish; performing induced culture on the high-quality parent fish, wherein the induced culture comprises nutrient enrichment and temperature induction; the temperature induction time is less than or equal to 35 days to promote the ovary maturation of the parent fish. Through an indoor induction mode combining low-temperature energy storage, gradient rewarming and nutrient enrichment feed, the maturation rate of the female plectropomus leopardus ovary can be remarkably increased to 85% or above, and the maturation period is shortened to be within 40 days. The method is suitable for a standardized breeding process of an indoor parent fish breeding workshop, effectively realizes synchronous maturation and quality improvement of the parent fish group ovary, provides a stable parent guarantee for indoor artificial breeding of plectropomus leopardus, and has a good popularization and application prospect.

The invention discloses application of spermidine in preparation of an agent for resisting mitochondrial oxidative damage and copper death damage, and relates to the technical field of biology. The invention provides an application of spermidine in preparing an agent for resisting mitochondrial oxidative damage and copper death damage, and further provides an application of spermidine in inhibiting copper death induced by copper sulfate and relieving iron-sulfur cluster protein loss and ester acylation protein aggregation induced by copper accumulation. The spermidine can obviously relieve cell viability decline induced by copper sulfate, reverse ROS and MDA level increase and mitochondrial membrane potential decline induced by copper sulfate and relieve iron-sulfur cluster protein loss and ester acylation protein aggregation induced by copper accumulation, and has obvious effects of inhibiting mitochondrial oxidative damage and copper death. The invention provides a method for effectively relieving copper death of ovarian granular cells, and solves the problem that the existing antioxidant and cytoprotective agent for resisting mitochondrial oxidative damage generate side effects in the use process.